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Certain inflammatory stimuli such as thioglycollate medium, asbestos, and endo- 
toxin are able to elicit macrophages into the peritoneal cavity of mice which synthesize 
and secrete increasing amounts of the neutral protease, plasminogen activator (1, 2). 
The  product  of the  interaction  of this  enzyme  with  the  circulating  proenzyme 
plasminogen is another neutral protease, plasmin, that is known to activate certain 
enzyme cascades relevant to the inflammatory response, viz., the complement (3), the 
clotting (4),  and the kinin systems (5).  Macrophages are an important cell type in 
chronic inflammatory lesions and it has previously been suggested that plasminogen- 
activator production by macrophages might play a role in the traffic of macrophages 
through the body (6).  The inhibition of enzyme production by anti-inflammatory 
glucocorticoids and hence inhibition of cell migration might account for some of the 
anti-inflammatory properties of these drugs (6). In contrast, agents such as phorbol 
myristate acetate, eoncanavalin A, and lymphocyte-conditioned medium can cause 
macrophages to produce more enzyme (7, 8). Little is known about how macrophages 
modulate plasminogen activator levels in response to the various agents and a study 
of the regulation of enzyme production might be important for the understanding of 
maerophage physiology and function. In addition, information about the anti-inflam- 
matory properties  of glucocorticoids and  about  the  mechanism of action of these 
drugs at a cellular level might be obtained by studying how they inhibit plasminogen- 
activator production by macrophages. 
Recently, several  mouse monocyte-macrophage tumor lines have been shown to 
exhibit certain properties similar to their nonneoplastic counterparts, viz., adherence 
properties, phagocytosis, lysozyme  synthesis, production of  colony-stimulating  activity, 
receptors for Fc and complement, the ability to lyse tumor cell targets, and prosta- 
glandin synthesis (9,  10). Thus, these cell lines offer the potential as models to study 
monoeyte-macrophage physiology and  function and, because  large populations of 
homogeneous cells can be obtained, can provide sufficient material for the isolation 
of receptors, enzymes, etc. In addition, the problem of contaminating cell types in 
tissue culture experiments is avoided. 
We show here that one such macrophage cell line, RAW264.10, synthesizes and 
secretes plasminogen activator spontaneously and that the synthesis of the enzyme 
can be inhibited by low concentrations of anti-inflammatory glucoeorticoids but is 
stimulated by low concentrations of the tumor promoter, phorbol myristate acetate. 
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FIo.  l.  Fibrinolysis by RAW264.10 cells. Varying numbers of washed cells were plated in duplicate 
cultures on msI-fibrin-coated Linbro wells (FBI6-24TC)  in Dulbecco's minimum essential medium 
(MEM) containing 5% acid-treated, heat-inactivated fetal bovine serum (ATHIFBS)  (  ) or 5% 
of plasminogen-depleted ATHIFBS  (- - -). The total  volume was 2 ml and 0.2-ml samples were 
removed as indicated (1). The following cell numbers were plated: 2  x  105 (O); 4  X  105 (I-'1); and 
8  x  105 (ZX). Each well contained 10 ~g fibrin/cm  2, with a total radioactivity of 6  ×  104 cpm. 
Materials and Methods 
Except when otherwise stated, all  reagents and procedures were as previously described (1, 
6). Phorbol myristate acetate and phorbol were obtained from Consolidated Midland Corpo- 
ration, Brewster, N. Y. 
RA W264.10 Cell Line.  This is a clone derived from RAW264,  a BALB/c tumor induced by 
Abelson  leukemia  virus  whose  macrophage nature  has  previously  been  described  (9). All 
incubations were carried out at 37°C in a 5% CO2-95% air atmosphere. 
Results 
Plasminogen-Dependent Fibrinolysis by  RA W264. I0.  For  monitoring  the  fibrinolytic 
activity of RAW264.10  cells,  varying numbers of washed cells were plated  directly 
onto t25I'-fibrin  and  the fibrinolytic activity measured by counting  released radioac- 
tivity at various time points. As can be seen in Fig.  1, after an initial short lag period, 
there is an approximately linear fibrinolytic activity detected in these cells which  is 
predominantly plasminogen dependent. 
Inhibition  of  the  Secretion  of  Plasmmogen  Activator  by  Anti-Inflammatory  Glucocorti- 
coids.  Serum-free medium was collected from the cultures of RAW264.10  cells and 
assayed for plasminogen activator. As can be seen from Table I, these cells,  as has 
been shown  for activated mouse macrophages, secrete plasminogen activator.  Anti- 
inflammatory glucocorticoids at low concentrations inhibit the synthesis and secretion 
of plasminogen activator from activated mouse macrophages (6). In Table I, the effect 
of 10  -7 M  dexamethasone on the extracellular  and cell-associated enzyme levels in 
RAW264.10  cells is shown.  As with peritoneal macrophages, this anti-inflammatory 
agent is able to decrease the enzyme levels without affecting the secretion of another 
enzyme, lysozyme (Table I). HAMILTON, RALPH, AND MOORE  BRIEF  DEFINITIVE REPORT 
TABLe  I 
Effect of Dexamethasone on the Secretion of Plasminogen Activator and Lysozyme 
813 
Plasmogen activator* 
Drug in the medium  l,ysozyme secreted 
Extracellular  Cell associated 
U/mg cell protean*  p.g/mg cell protein 
None  1,080  320  12.8 
Dexamethasone  (10  -7 M)  277  50  11.7 
RAW264.10 cells were washed in 1)ulbecco's MEM and placed at 4  ×  l0  s cells in Dulbecco's MEM containing 
0 05%  lactatbumin  hydrolysate  (LH)  in duplicate  Linbro  wells (Linbro Chemical  Co.,  New  Haven, Conn3. 
Dexamethasonc was added at the start of the culture. After 24 h, the serum-free conditioned medium (CM) was 
collected, the cultures washed two times with phosphate-buffered  saline (PBS), the cells lysed by the addition of 
Triton X-100 (Rohm & Haas Co., Philadelphia, Pa.)  (0.2%  vol/vol in water), and scraped from the surface of 
the dish  with  a  plastic policeman.  The conditioned  media and  the cells were  then  assayed  for plasminogen 
activator and the conditioned media for lysozyme (I, 6). 
* No  plasminogen-independent  fibrinolysis could  be  detected  when  plasminogen  was  omitted  fiom  the  assay 
mixture. 
*  I U of plasminogen activator is defined as the amount  that releases 10q, of the initial radioactivity in 4 h  (I). 
TABLE II 
Relative Effect of Glucocorticoids on Plasminogen-Activator Secretion 
Drug  Control 
l0  -7 M  tTt 
PBS  100 
Dexamet hasone  24.7 
Prednisolone  28 I 
Fludrocortisone  31.5 
Hydrocortisone  41.0 
Cortieosterone  47.8 
Cortexolone  52.7 
Desoxycor ticosterone  60.7 
Aldosterone  91.3 
Progesterone  IIKI 
fl-Estradiol  100 
Testosterone  100 
A similar experimental protocol to Fig  2 and Table I was used. The results are expressed as percentages 
of the activity present in the control untreated cultures. The mean plasminogen-actlvator content of the 
control CM was 1,010 U/rag cell protein. The cell protein did not vary significantly between the control 
and experimental cultures 
A  dose response for dexamethasone inhibition on the extracellular enzyme levels is 
depicted  in  Fig.  2.  The  lysozyme  secretion  was  not  affected  by  these  doses  of 
dexamethasone  (J. A. Hamilton, unpublished observations). 
It  has  previously been shown  that  for the glucocorticoids,  the anti-inflammatory 
drugs  are  the  most  effective  at  decreasing  plasminogen-activator  levels  of  mouse 
macrophages  (6).  The  relative  abilities  of a  series  of glucocorticoids  at  10 -7  M  to 
suppress  extracellular  plasminogen-activator  levels  from  the  RAW264.10  cells  are 
listed  in Table  II.  The  relative  inhibitory potencies  are similar  for these  neoplastic 
cells and for the peritoneal mouse macrophages  (6). 
Stimulation  of  the  Secretion  of  Plasminogen  ,Activator  by  Phorbol  Myristate  Acetate 
(PMA).  PMA,  a  tumor  promoter  in  a  mouse  skin  carcinogenesis  model  (11),  has 
been shown to induce and stimulate  plasminogen-activator  production from mouse 
peritoneal macrophages  (7). The parent alcohol, phorbol, is inactive. In Fig. 3, PMA 
is shown to increase  plasminogen-activator  secretion  from  RAW264.10  cells  at  low 
concentrations whereas phorbol itself is inactive. The cell-associated enzyme levels are 
increased at most two- to threefold (J. A. Hamilton, unpublished observations). 814  HAMILTON,  RALPH,  AND  MOORE  BRIEF  DEFINITIVE  REPORT 
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FIG.  2.  Effect of dexamethasone on plasminogen-activator secretion from RAW264.10 cells. 4  X 
105 cells were washed in Dulbecco's MEM and placed in Dulbecco's MEM  +  0.05% LH in the 
presence of different concentrations of dexamethasone (duplicate cultures). After 24 h the CM was 
collected and assayed for plasminogen activator (6). The results are expressed as percentages of the 
activity present in the control untreated culture. Plasminogen-activator content of control CM was 
890 U/mg cell protein. The cell protein content at the end of the cultures did not vary significantly 
between the control and experimental cultures. 
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FIG.  3.  Effect  of PMA  and  phorbol  on  secretion  of plasminogen activator.  After  washing in 
Dulbecco's MEM, 4  ×  105 RAW264.10 cells were plated onto wells of Linbro trays in Dulbecco's 
MEM +  0.05% LH in the presence of PMA (O) or phorboi (0). At 24 h, the CM was collected and 
assayed for plasminogen activator. The amount of plasminogen activator secreted per milligram of 
cell protein in the control untreated cultures was defined as 1 (the actual mean value was 790 U/mg 
cell protein).  No plasminogen-independent fibrinolytic activity was detected in the cultures. The 
cell protein content at the end of the cultures did not vary significantly between the control and 
experimental cultures. 
Discussion 
The above study indicates  that a  mouse macrophage cell line  (RAW264.10)  can 
spontaneously synthesize and secrete the neutral protease, plasminogen activator. In 
addition,  this  line  produces  less  enzyme in  the  presence  of low  concentrations  of 
glucocorticoids but more enzyme when treated with the tumor promoter, PMA. HAMILTON, RALPH, AND MOORE  BRIEF DEFINITIVE REPORT  815 
Certain  irritants, such as thioglycollate medium and asbestos fibers, are able to 
elicit macrophages into the peritoneal cavity of mice which synthesize much higher 
levels of plasminogen activator than the resident, unstimulated macrophages (1, 2). 
The  amount of enzyme produced  by the  RAW264.10  line is  comparable  to  that 
produced by the so-called activated macrophages and it is possible that this line is 
expressing  a  permanent  state  of activation.  Further  experiments  are  needed  to 
understand the significance of the enzyme synthesis for RAW264.10 metabolism. 
We have shown here that low doses of dexamethasone can inhibit production of 
plasminogen activator by the RAW264.10 line and the spectrum of the abilities of 
other  glucocorticoids  to  inhibit  enzyme  production  is  similar  to  that  found  for 
thioglycollate-induced mouse peritoneal macrophages (6). Interestingly, the relative 
potencies  of these  drugs  parallels  their  abilities  to  function as  anti-inflammatory 
agents (12). Also, as with thioglycollate- and asbestos-induced macrophages, lysozyme 
secretion is not inhibited. These observations suggest that the cell line can modulate 
its enzyme production in response to glucocorticoids in a  similar manner to mouse 
peritoneal macrophages. Thus the cell line may provide a  useful model system for 
studying glucocorticoid-receptor interaction and possibly for receptor isolation from 
the macrophage. These cells may also enable the details for the mechanism of the 
glucocorticoid control of enzyme synthesis to be elucidated. 
The cocarcinogenic effects of PMA and other promoting substances are known to 
be  inseparable  from a  powerful inflammatory response that  is associated with the 
presence of lymphocytes and  macrophages in  the affected areas of skin  (t3),  and 
protease levels in the skin are shown to increase in conjunction with the inflammatory 
response. Furthermore, nanomolar concentrations of tumor-promoting phorbol esters 
(but not their inactive analogues) induce changes in cultured cells that resemble those 
seen on transformation with either chemical carcinogens or tumor viruses, and further 
enhance the expression of these transformation-specific phenotypic features in already 
transformed  cells  (14).  They  also  reversibly  inhibit  terminal  differentiation in  a 
number of different cell types (14). We have shown here that the cell line RAW264.10 
can increase plasminogen-activator production in response to low concentrations of 
PMA with a similar dose response to that found with mouse peritoneal macrophages 
and, as with the peritoneal macrophages, the parent  alcohol is without effect (7). 
These observations suggest that the cell line possesses similar receptors or other cellular 
components to peritoneal macrophages which can respond to PMA and again points 
to the possible usefulness of this line in the study of macrophage physiology. 
In summary, we suggest that the macrophage tumor cell line, RAW264.10, provides 
a  cell  type which should be  useful  in  delineating how  macrophages  regulate  the 
production of plasminogen activator. The cell line may be useful for the isolation of 
receptors for glucocorticoids and for studying molecular events associated with PMA- 
cell interactions. Studies on the relationship between plasminogen activator synthesis 
and the other functional properties of RAW264.10  (9,  10)  are currently in progress. 
Summary 
The  macrophage  cell  line,  RAW264.10,  synthesizes  and  secretes  plasminogen 
activator. Production of this enzyme is inhibited by low concentrations of glucocor- 
ticoids and increased by phorbol myristate acetate. It is proposed that this line could 
be  a  suitable  model  for  the  regulation  of enzyme synthesis by  mouse  peritoneal 
macrophages. 816  HAMILTON, RALPH, AND MOORE  BRIEF  DEFINITIVE REPORT 
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